Pricing Cures For Sickle Cell Disease: Sen. Cassidy Weighs In
Price decisions based on straight calculation of medical costs avoided may overestimate value of a cure, Cassidy warns.
You may also be interested in...
MIT Center for Biomedical Innovation is proposing creation of Orphan Reinsurance Benefit Managers as one mechanism to help finance curative cellular and gene therapies. The idea may or may not prove viable – but it is a reminder that “middlemen” aren’t likely going away even if rebates do.
Legislation from Sens. Bill Cassidy and Mark Warner would eliminate barriers to value-based contracting for drugs reimbursed by public payers.
Purchasing contract for state Medicaid and Corrections programs would last up to five years and aim to treat more than 10,000 patients in first year.